BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33829319)

  • 21. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis.
    Wang X; Zhu Q; Yan Z; Shi Z; Xu Y; Liu Y; Li Y
    Mult Scler Relat Disord; 2023 Jul; 75():104740. PubMed ID: 37146422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    Preziosa P; Pagani E; Meani A; Marchesi O; Conti L; Falini A; Rocca MA; Filippi M
    J Neurol; 2023 Feb; 270(2):810-823. PubMed ID: 36201016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
    Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
    J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-Gaussian diffusion MRI of gray matter is associated with cognitive impairment in multiple sclerosis.
    Bester M; Jensen JH; Babb JS; Tabesh A; Miles L; Herbert J; Grossman RI; Inglese M
    Mult Scler; 2015 Jun; 21(7):935-44. PubMed ID: 25392318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resolving the cognitive clinico-radiological paradox - Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis.
    Johnen A; Schiffler P; Landmeyer NC; Tenberge JG; Riepl E; Wiendl H; Krämer J; Meuth SG
    Cortex; 2019 Dec; 121():239-252. PubMed ID: 31654896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    Zhuo Z; Li Y; Duan Y; Cao G; Zheng F; Ding J; Tian D; Wang X; Wang J; Zhang X; Li K; Zhou F; Huang M; Li Y; Li H; Zeng C; Zhang N; Sun J; Yu C; Han X; Haller S; Barkhof F; Shi F; Liu Y
    J Neurol; 2021 May; 268(5):1808-1817. PubMed ID: 33387013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The heterogeneity of tissue destruction between iron rim lesions and non-iron rim lesions in multiple sclerosis: A diffusion MRI study.
    Hu H; Ye L; Ding S; Zhu Q; Yan Z; Chen X; Chen G; Feng X; Li Q; Li Y
    Mult Scler Relat Disord; 2022 Oct; 66():104070. PubMed ID: 35914471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis.
    Sethi V; Yousry T; Muhlert N; Tozer DJ; Altmann D; Ron M; Wheeler-Kingshott C; Miller DH; Chard DT
    J Neurol Neurosurg Psychiatry; 2016 Jul; 87(7):750-3. PubMed ID: 26272028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.
    Calabrese M; Agosta F; Rinaldi F; Mattisi I; Grossi P; Favaretto A; Atzori M; Bernardi V; Barachino L; Rinaldi L; Perini P; Gallo P; Filippi M
    Arch Neurol; 2009 Sep; 66(9):1144-50. PubMed ID: 19752305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    Zivadinov R; Bergsland N; Hagemeier J; Carl E; Kolb H; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 May; 388():175-181. PubMed ID: 29627017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional white matter and gray matter damage and cognitive performances in multiple sclerosis according to sex.
    Tedone N; Preziosa P; Meani A; Pagani E; Vizzino C; Filippi M; Rocca MA
    Mol Psychiatry; 2023 Apr; 28(4):1783-1792. PubMed ID: 36806391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased cortical lesion load contributed to pathological changes beyond focal lesion in cortical gray matter of multiple sclerosis: a diffusion kurtosis imaging analysis.
    Zhu Q; Yan Z; Shi Z; Luo D; Ding S; Chen X; Li Y
    Cereb Cortex; 2023 Oct; 33(21):10867-10876. PubMed ID: 37718158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study.
    Damjanovic D; Valsasina P; Rocca MA; Stromillo ML; Gallo A; Enzinger C; Hulst HE; Rovira A; Muhlert N; De Stefano N; Bisecco A; Fazekas F; Arévalo MJ; Yousry TA; Filippi M
    AJNR Am J Neuroradiol; 2017 Jan; 38(1):18-24. PubMed ID: 27686487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients.
    Hojjat SP; Cantrell CG; Carroll TJ; Vitorino R; Feinstein A; Zhang L; Symons SP; Morrow SA; Lee L; O'Connor P; Aviv RI
    Mult Scler; 2016 Nov; 22(13):1685-1694. PubMed ID: 26846987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of white matter in cognitive impairment among relapsing remitting multiple sclerosis patients.
    Elkhooly M; Bao F; Raghib M; Millis S; Bernitsas E
    Mult Scler Relat Disord; 2023 Nov; 79():105030. PubMed ID: 37837669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.